Compare Ascendis Pharma A/S (ASND) vs Macy's Inc (M) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Macy's Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Macy's Inc trades at $22.6 (market cap $5.96B). The key difference: Ascendis Pharma A/S is far larger — about 3× Macy's Inc's market cap, and Macy's Inc pays a 3.38% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | M | |
|---|---|---|
Market Cap | $17.74B | $5.96B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $25.96 |
52-Week Low | $163.32 | $11.90 |
Enterprise Value | $18.11B | $9.77B |
Dividend Yield | — | 3.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Macy's (M) trades at $22.64, down 0.18% on the day, with a bullish technical signal and strong recent earnings beats. The stock shows attractive valuation metrics including a P/E of 9.36 and P/S of 0.27, while profitability metrics like ROE of 14.36% indicate efficient capital use. Recent news highlights Berkshire Hathaway's new 3.04 million-share stake and the company's 'Bold New Chapter' strategy driving comparable sales growth.
The outlook for Macy's is cautiously optimistic with a consensus price target of $24.83 offering ~10% upside. Key opportunities include luxury brand expansion and digital transformation, while risks involve margin pressure from restructuring and competitive retail headwinds. The stock presents a value opportunity if turnaround execution continues successfully.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Macy's Inc
Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.
Read more on M →
